Predicting heart failure using the plasma proteome
To determine whether the plasma proteome adds value to established predictors in heart failure (HF) with reduced ejection fraction (HFrEF). We sought to derive and validate a plasma proteomic risk score (PRS) for survival in patients with HFrEF (HFrEF-PRS).
Until recently, proteomics had not been as thoroughly explored partly due to comparatively low-throughput. However, emerging proteomic technologies have recently matured and newer high-throughput techniques now allow larger scale proteomic characterization. One of these newer technological innovations, enhanced aptamer-based assays, has enabled a massively expanded candidate approach that borders on true proteomics in scale; thousands of protein-derived factors can be efficiently assayed simultaneously in a small biologic sample. In this webinar, you will explore this new large-scale protein array using an established HF patient registry to understand how the plasma proteome could meaningfully predict the risk of death or HF worsening and add to best conventional risk stratification, including clinical score and natriuretic peptides. By using the circulating proteome to improve risk prediction, it could add a new tool to help manage patients with HF and contribute to discovery of novel HF markers and pathways.
David E. Lanfear, MD, MS, FAHA, FACC, FHFSA
Section Head, Advanced Heart Failure and Transplant Cardiology Co-Director, Center for Individualized and Genomic Medicine Research Professor of Medicine, WSU-SoM Henry Ford Hospital
DAVID E. LANFEAR, MD, MS, Research Professor of Medicine, is Head of the Advanced Heart Failure and Transplant Cardiology at Henry Ford Hospital in Detroit, and Co-Director of the Center for Individualized and Genomic Medicine Research (CIGMA). Dr. Lanfear is a practicing transplant cardiologist, a clinician scientist with a track record of NIH-funded projects on precision medicine and genomics as well as an active trialist with experience in single and multicenter clinical trials. He has more than 140 published manuscripts, reaching high-impact journals including JAMA and NEJM. He is Associate Editor at Circulation: Heart Failure and is on the Editorial Boards of JCF, Heart Failure Reviews, JACC:Cardio-oncology, JACC: Basic to Translational Science.
WebinarMillions for Proteomics Research in the Peer Reviewed Medical Research Program
How SomaLogic Technologies can give your research programs an edge
WebinarA proteomics signature of NASH
There is a high unmet need for non-invasive tests that can robustly and reliably assess NAFLD for diagnosis, prognosis, and monitoring purposes. Large-scale profiling of serum/plasma proteins (proteomics) increasingly demonstrates utility to identify changes that accurately reflect and predict disease states and outcomes, including the fibrosis component of NASH that is driven by disease activity and remains the most robust histological marker of prognosis.
WebinarEarly Detection, Risk Stratification, and Drug Target Identification in Pulmonary Arterial Hypertension with Plasma Proteomics
Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.